Press Releases
In the News
2012
-
December 20, 2012Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing
-
October 30, 2012Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy
-
October 10, 2012Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 17th Annual World Muscle Society Congress
-
October 3, 2012Ultragenyx to Present at the 11th Annual BIO Investor Forum in San Francisco
-
August 30, 2012Ultragenyx to Present at the Stifel Nicolaus Weisel Healthcare Conference 2012 in Boston
-
August 9, 2012Ultragenyx to Present at the Canaccord Genuity 32nd Annual Growth Conference on August 16, 2012
-
August 7, 2012Ultragenyx to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference on August 15
-
July 5, 2012Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy, a Rare Neuromuscular Disease
-
May 1, 2012Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
-
April 23, 2012Ultragenyx Relocates Company Headquarters to Support Operational Expansion
-
April 18, 2012Ultragenyx Appoints Shalini Sharp as Chief Financial Officer and Senior Vice President, Finance
-
March 28, 2012Ultragenyx Granted Orphan Designation in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
-
March 8, 2012Ultragenyx Announces the Completion of the Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
-
February 28, 2012Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
-
January 5, 2012Ultragenyx In-Licenses Therapeutic Program for Rare Genetic Disease Mucopolysaccharidosis Type 7 from St. Louis University